Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.

ABSTRACT: Checkpoint blockade with antibodies specific for cytotoxic T lymphocyte-associated protein (CTLA)-4 or programmed cell death 1 (PDCD1; also known as PD-1) elicits durable tumor regression in metastatic cancer, but these dramatic responses are confined to a minority of patients. This suboptimal outcome is probably due in part to the complex network of immunosuppressive pathways present in advanced tumors, which are unlikely to be overcome by intervention at a single signaling checkpoint. Here we describe a combination immunotherapy that recruits a variety of innate and adaptive immune cells to eliminate large tumor burdens in syngeneic tumor models and a genetically engineered mouse model of melanoma; to our knowledge tumors of this size have not previously been curable by treatments relyin

SUBMITTER: Moynihan KD 

PROVIDER: S-EPMC5209798 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature